title: Mycobacterium haemophilum infection in an SLE patient on mycophenolate mofetil.
abstract: We describe a case of Mycobacterium haemophilum in an immunocompromised patient with systemic lupus erythematosus (SLE). Mycobacterium haemophilum is a recently described pathogen which has not been previously described either in SLE patients or patients on Mycophenolate Mofetil. Mycobacterium haemophilum can be difficult to diagnose, as it may not have the granulomas characteristic of atypical mycobacterial infections. Combination therapy with at least two drugs for several months is required and the outcome depends on the patient's underlying immunocompromised state. Our report highlights the need for early diagnosis and treatment of Mycobacterium haemophilum in immunocompromised patients with SLE.
authors.affiliation: Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore. Cheng_Lay_Teh@ttsh.com.sg
authors.forename: C L
authors.initials: CL
authors.lastname: Teh
authors.forename: K O
authors.initials: KO
authors.lastname: Kong
authors.forename: A P Y
authors.initials: AP
authors.lastname: Chong
authors.forename: H
authors.initials: H
authors.lastname: Badsha
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007538:Isoniazid / Q000627:therapeutic use; D007866:Leg / Q000382:microbiology / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy* / Q000382:microbiology; D018482:Muscle, Skeletal / Q000382:microbiology / Q000473:pathology; D009164:Mycobacterium Infections / Q000150:complications* / Q000382:microbiology; D018393:Mycobacterium haemophilum; D009173:Mycophenolic Acid / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D004977:Ethambutol; D003520:Cyclophosphamide; D017291:Clarithromycin; D009173:Mycophenolic Acid; D007538:Isoniazid; D012293:Rifampin